1. Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children
- Author
-
Nader Shaikh, Alejandro Hoberman, Alan Wells, Patrick J. Tate, Eric J. Friedlander, Hui Liu, and Chung-Chou Ho Chang
- Subjects
medicine.medical_specialty ,Emergency Use Authorization ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Primary care ,Sensitivity and Specificity ,COVID-19 Serological Testing ,Food and drug administration ,Young Adult ,Antigen ,Internal medicine ,medicine ,Confidence Intervals ,Humans ,Symptom onset ,Child ,Antigens, Viral ,business.industry ,SARS-CoV-2 ,Age Factors ,COVID-19 ,Infant ,Cross-Sectional Studies ,COVID-19 Nucleic Acid Testing ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Symptom Assessment ,business ,Lateral flow immunoassay - Abstract
* Abbreviations: CI — : confidence interval COVID-19 — : coronavirus disease 2019 PCR — : polymerase chain reaction SARS-CoV-2 — : severe acute respiratory syndrome coronavirus 2 Abbott BinaxNOW (a bedside lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen) is widely available under US Food and Drug Administration emergency use authorization for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in symptomatic patients within 7 days of symptom onset. Its diagnostic performance in symptomatic children has not been evaluated. Cross-sectional study of symptomatic children ≤20 years presenting for care to 1 of 2 primary care practices in December 2020, during which time coronavirus disease 2019 (COVID-19) rates were … Address correspondence to Nader Shaikh, MD, MPH, University of Pittsburgh Medical Center, Children’s Hospital of Pittsburgh, 1 Children’s Hospital Dr, 4401 Penn Ave, Pittsburgh, PA 15224. E-mail: nader.shaikh{at}chp.edu
- Published
- 2021